Ever wondered if Arrowhead Pharmaceuticals’ meteoric rise means the best value is behind it, or if there is still room to capitalize? Let’s break down whether now is actually a good time to buy in.
Fintel reports that on November 19, 2025, RBC Capital maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with a ...
Fintel reports that on November 19, 2025, Piper Sandler maintained coverage of Arrowhead Pharmaceuticals (NasdaqGS:ARWR) with ...
Arrowhead Pharmaceuticals' fair value estimate has recently risen from $47.50 to $55.00 per share, signaling an improved outlook following the FDA approval of Redemplo. This updated price target ...
Arrowhead Pharmaceuticals faces key FDA decisions, legal challenges, and trial results. Read the latest analysis on the stock ...
The clearance of Redemplo for a rare genetic disorder marks Arrowhead’s transition, after two decades, into a ...
The FDA approval of the siRNA drug Redemplo caps off a tumultuous 12 months for Arrowhead, whose partnership with Sarepta ...
Detailed price information for Arrowhead Pharma (ARWR-Q) from The Globe and Mail including charting and trades.
Pharmaceutical Technology on MSN
Arrowhead nets first commercial win as siRNA drug garners FDA approval
Redemplo’s approval in familial chylomicronemia syndrome places the drug in competition with Ionis’ Tryngolza.
After falling to the Broncos last week, the Chiefs will now face an equally formidable foe in the Indianapolis Colts. Here's ...
The Colts are coming off their bye week and the Chiefs have lost two straight. Kansas City is 0-5 in one-possession games.
Which Is a Better Investment, Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. Stock?
Learn more about whether Arrowhead Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback